Meeting
2022 ASCO Annual Meeting
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) versus intravenous chemotherapy in unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer: Interim analysis of Indian randomized control trial.
Authors
S.P. Somashekhar
Manipal Comprehensive Cancer Center, Bangalore, India
S.P. Somashekhar , Rohit Kumar , Amit Rauthan , Poonam Patil , Priya Kapoor , Susmita Rakshit , Ashwin K. Rajgopal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
REF/2018/08/021223
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5524)
DOI
10.1200/JCO.2022.40.16_suppl.5524
Abstract #
5524
Poster Bd #
403
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and efficacy of PIPAC in ovarian cancer patients with peritoneal metastases: A first-in-US phase I study.
First Author: Rosemary Senguttuvan
Poster
2023 ASCO Genitourinary Cancers Symposium
Sequential enfortumab vedotin (EV) after platinum-based chemotherapy in metastatic or locally advanced urothelial cancer: Complete response, bladder preservation and survival.
First Author: Putao Cen
Poster
2020 Gastrointestinal Cancers Symposium
Palliative systemic chemotherapy with or without pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin (PIPAC C/D) for gastric cancer with peritoneal metastasis: A propensity score analysis.
First Author: Vladimir Khomiakov
Poster
2020 Gastrointestinal Cancers Symposium
Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis.
First Author: Mehdi Javanbakht